miRecule and Sanofi have partnered to pioneer innovative approaches in rare diseases and advance a novel RNA therapeutic for patients with the genetic disorder FSHD. miRecule’s DREAmiR™ discovery platform, combined with Sanofi’s Nanobody® technology, enables the...
miRecule Enters into Strategic Collaboration with Sanofi to Accelerate Discovery and Development of a Best-in-Class Antibody-RNA Conjugate to Treat Facioscapulohumeral Muscular Dystrophy (FSHD)
Partnership combines miRecule’s unique RNA therapeutic discovery and conjugation platforms with Sanofi’s NANOBODY® technology to create a groundbreaking treatment for FSHD miRecule will receive an upfront payment with potential future milestone payments of nearly $400...
SOLVE FSHD Invests US $1 Million in miRecule to Accelerate Development of Best-in-Class Antibody-RNA Conjugate to Treat Facioscapulohumeral Muscular Dystrophy
Read the press release here: SOLVE-FSHD Invests US 1 Million in miRecule to Accelerate Development of Best-in-Class Antibody-RNA-Conjugate to Treat Facioscapulohumeral Muscular Dystrophy_
Read the full story here: Global News Wire
Fore media inquiries
Fore investment inquiries